ADAM17
ADAM17, also known as TACE, CD156B and cSVP, is a transmembrane metalloprotease that sheds the ectodomains of many cell-surface proteins. It was named tumour necrosis factor-alpha converting enzyme for its release of soluble TNF from its membrane-bound precursor. Browse Assay Genie's current range of ADAM17 research reagents below, or read on for the biology behind the target.
ADAM17 is a transmembrane metalloprotease that mediates ectodomain shedding of a large number of membrane proteins, including adhesion proteins, growth factor precursors and cytokines important for inflammation and immunity. Its best-known activity is cleavage of the membrane-bound TNF precursor to the mature soluble form. It also releases p75 and p55 TNF receptors, interleukin 1 receptor type II, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein, and it releases soluble JAM3 from the endothelial cell surface.
The protease also acts on immune and signalling molecules. It cleaves Notch to generate the membrane-associated fragment NEXT, and so activates the Notch pathway. It cleaves LAG3 and IL-6 receptor to release their secreted forms, and sheds TREM2 ectodomain. On stimulated NK cells it cleaves FCGR3A, which increases NK cell motility and detachment from opsonised target cells. Shedding of platelet GP1BA links it to haemostasis, and it takes part in the processing of ACE2, the cellular receptor for SARS-CoV and SARS-CoV-2, so it may influence viral infection.
The ADAM17 gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family, membrane-anchored proteins related to snake venom disintegrins and implicated in cell-cell and cell-matrix interactions. The preproprotein is proteolytically processed to give the mature protease. The protein is also designated CD156B, and its previous HGNC name was tumour necrosis factor, alpha, converting enzyme. Elevated expression has been seen in specific cell types from patients with psoriasis, rheumatoid arthritis, multiple sclerosis and Crohn's disease, suggesting a role in autoimmune disease.
ADAM17 releases soluble TNF from its membrane-bound precursor and sheds cytokine receptors, making it central to inflammatory signalling.
Elevated expression in cells from psoriasis, rheumatoid arthritis, multiple sclerosis and Crohn's disease patients suggests a role in autoimmunity.
ADAM17 cleaves Notch to generate NEXT and releases EGF receptor ligands and TGF-alpha, shaping cell signalling.
ADAM17 sheds LAG3, FCGR3A, TREM2 and IL-6 receptor, and processes ACE2, the receptor for SARS-CoV and SARS-CoV-2.
ADAM17 is a cell-membrane metalloprotease that cleaves the ectodomains of many transmembrane proteins, releasing soluble forms. Substrates include TNF, IL-6 receptor, TGF-alpha, L-selectin, LAG3, TREM2 and the amyloid precursor protein. It also cleaves Notch, activating that pathway.
TACE stands for tumour necrosis factor-alpha converting enzyme, the previous HGNC name for the gene. It reflects the protease's cleavage of membrane-bound TNF to soluble TNF. Other aliases are CD156B and cSVP; the official symbol is ADAM17.
Mouse and rat both have an Adam17 ortholog. Elevated expression in specific cells from psoriasis, rheumatoid arthritis, multiple sclerosis and Crohn's disease patients suggests a role in autoimmune disease. Check the datasheet of any product for its validated reactivity.
Other ADAM and ADAMTS family metalloproteases with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P78536; product specifications from Assay Genie datasheets.